Kewaunee Reports Q4 Revenue of $71.4M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Reports Q4 revenue $71.4M vs $77.15M last year. "Fiscal year 2026 was an excellent year for Kewaunee, particularly in light of the challenging operating environment in which it was delivered," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Our team managed through these conditions effectively, maintaining a strong level of EBITDA while making meaningful progress on the strategic priorities that will support Kewaunee's next phase of growth. We continued to invest in the Corporate platform required to scale as a public company, support future acquisitions, and accelerate our organic and inorganic growth strategy. We also made significant progress integrating Nu Aire, positioning the business for improved performance as life sciences market conditions recover, while strengthening our balance sheet through the servicing and repayment of acquisition-related debt."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KEQU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KEQU
About KEQU
Kewaunee Scientific Corporation is engaged in designing, manufacturing, and installation of laboratory, healthcare and technical furniture products. The Company’s products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, ultralow freezers, and epoxy resin work surfaces and sinks. Its segments include Domestic and International. The Domestic segment designs, manufactures, and installs scientific and technical furniture. The International segment consists of foreign subsidiaries. The Company's products are sold primarily through purchase orders and contracts submitted by customers through its dealers and its subsidiaries, and a national distributor. It has three manufacturing facilities that are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kewaunee Scientific Reports Decline in Q4 Profit
- Profit Decline: Kewaunee Scientific Corporation reported a fourth-quarter net profit of $3.39 million, or $1.13 per share, which represents a significant drop from last year's $4.85 million and $1.63 per share, indicating a weakening in the company's profitability.
- Adjusted Earnings: Excluding special items, the company reported adjusted earnings of $3.40 million, or $1.14 per share, which, while slightly higher than GAAP figures, still reflects overall profitability challenges.
- Revenue Drop: The company's fourth-quarter revenue fell to $71.40 million, a 7.5% decrease from $77.15 million last year, suggesting potential impacts on market demand that warrant attention for future sales strategies.
- Market Reaction: The dual decline in profit and revenue has led to a cautious market outlook for Kewaunee Scientific, which may affect its stock performance and investor confidence moving forward.
See More
Kewaunee Scientific Reports Strong FY 2026 Results Amid Challenges
- Significant Sales Growth: Kewaunee Scientific reported sales of $281.99 million for FY 2026, a 17.3% increase, demonstrating the company's ability to achieve robust growth post-Nu Aire integration despite market challenges, enhancing its competitive position.
- Profitability Fluctuations: Net earnings for FY 2026 were $9.62 million, down 15.7% from the previous year, reflecting pressures from high costs and project delivery timeline volatility, indicating a need for improved cost controls to maintain profitability.
- Strong International Performance: International sales reached $67.11 million, a 9.9% increase, showcasing the resilience of the international team in navigating geopolitical uncertainties through effective project execution and management, supporting future growth potential.
- Balance Sheet Improvement: The company successfully reduced long-term debt by approximately $20 million, improving its debt-to-equity ratio from 0.99 to 0.61, indicating enhanced financial health and laying the groundwork for future acquisitions and expansion.
See More
Kewaunee Reports Strong Fiscal Year 2026 Results with Revenue Growth
- Significant Sales Growth: Kewaunee achieved sales of $281.99 million in fiscal year 2026, representing a 17.3% increase compared to the previous year, indicating strong market demand post-Nu Aire integration and enhancing its position in the laboratory products sector.
- Profitability Fluctuations: Despite the sales growth, net earnings for fiscal year 2026 were $9.62 million, down 15.5% from $11.41 million the previous year, reflecting profitability pressures amid high costs and market volatility, necessitating further cost optimization to maintain margins.
- Strong International Performance: International sales reached $67.11 million, a 9.9% increase, demonstrating the company's resilience in the global market and robust project backlog despite heightened geopolitical uncertainties, bolstering confidence in future growth prospects.
- Improved Balance Sheet: The company successfully reduced long-term debt by approximately $20 million in fiscal year 2026, improving its debt-to-equity ratio from 0.99 to 0.61, indicating significant progress in financial health and laying a solid foundation for future expansion and acquisitions.
See More
Kewaunee Scientific Reports Fiscal Year 2026 Earnings
- Earnings Highlights: Kewaunee Scientific reported a Q4 GAAP EPS of $1.13, with revenue of $71.4 million reflecting a 7.5% year-over-year decline, indicating resilience amid market challenges.
- Annual Sales Growth: The company achieved $281.99 million in sales for fiscal year 2026, representing a 17.3% increase from $240.47 million in the previous year, showcasing positive performance in product demand and market share.
- Profitability Changes: Pre-tax earnings for the fiscal year were $13.73 million, down from $14.79 million the prior year, while net earnings decreased from $11.41 million to $9.62 million, reflecting the impact of cost pressures on profitability.
- Decline in EPS: Diluted earnings per share fell to $3.22 from $3.83 in the previous fiscal year, indicating challenges in profitability that may affect investor confidence.
See More
Kewaunee Scientific to Release Q4 and FY 2026 Financial Results on June 23
- Earnings Release Plan: Kewaunee Scientific Corporation plans to release its fourth quarter and fiscal year 2026 financial results on June 23, 2026, after market close, which is expected to provide investors with crucial performance data and future outlook.
- Company Background: Founded in 1906, Kewaunee is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, including steel and wood casework, fume hoods, and biological safety cabinets, showcasing its strong industry presence.
- Acquisition Details: The recently acquired subsidiary, Nu Aire, specializes in manufacturing biological safety cabinets and ultralow freezers, which complements Kewaunee's product portfolio and enhances its competitive edge in the market.
- Global Operations: Kewaunee operates multiple sales and manufacturing facilities across the U.S., India, and other countries, demonstrating its extensive international footprint and capability to serve global customers.
See More
Kewaunee Scientific Q3 Financial Highlights
- Earnings Performance: Kewaunee Scientific reported a Q3 GAAP EPS of $0.23, indicating stability in profitability despite facing market challenges.
- Revenue Growth: The company achieved revenues of $69.4 million in Q3, reflecting a year-over-year increase of 3.3%, showcasing sustained demand in the laboratory equipment market and an expanding customer base.
- Market Performance Analysis: Although the revenue growth rate is modest, the stable profitability and slight increase suggest that the company maintains a solid competitive position in the industry, potentially attracting more investor interest.
- Future Outlook: Kewaunee Scientific's financial performance lays a foundation for future growth, and management may leverage this positive trend to drive new product development and market expansion strategies.
See More
Kewaunee Scientific Reports Decline in Q4 Profit
- Profit Decline: Kewaunee Scientific Corporation reported a fourth-quarter net profit of $3.39 million, or $1.13 per share, which represents a significant drop from last year's $4.85 million and $1.63 per share, indicating a weakening in the company's profitability.
- Adjusted Earnings: Excluding special items, the company reported adjusted earnings of $3.40 million, or $1.14 per share, which, while slightly higher than GAAP figures, still reflects overall profitability challenges.
- Revenue Drop: The company's fourth-quarter revenue fell to $71.40 million, a 7.5% decrease from $77.15 million last year, suggesting potential impacts on market demand that warrant attention for future sales strategies.
- Market Reaction: The dual decline in profit and revenue has led to a cautious market outlook for Kewaunee Scientific, which may affect its stock performance and investor confidence moving forward.
See More
Kewaunee Scientific Reports Strong FY 2026 Results Amid Challenges
- Significant Sales Growth: Kewaunee Scientific reported sales of $281.99 million for FY 2026, a 17.3% increase, demonstrating the company's ability to achieve robust growth post-Nu Aire integration despite market challenges, enhancing its competitive position.
- Profitability Fluctuations: Net earnings for FY 2026 were $9.62 million, down 15.7% from the previous year, reflecting pressures from high costs and project delivery timeline volatility, indicating a need for improved cost controls to maintain profitability.
- Strong International Performance: International sales reached $67.11 million, a 9.9% increase, showcasing the resilience of the international team in navigating geopolitical uncertainties through effective project execution and management, supporting future growth potential.
- Balance Sheet Improvement: The company successfully reduced long-term debt by approximately $20 million, improving its debt-to-equity ratio from 0.99 to 0.61, indicating enhanced financial health and laying the groundwork for future acquisitions and expansion.
See More
Kewaunee Reports Strong Fiscal Year 2026 Results with Revenue Growth
- Significant Sales Growth: Kewaunee achieved sales of $281.99 million in fiscal year 2026, representing a 17.3% increase compared to the previous year, indicating strong market demand post-Nu Aire integration and enhancing its position in the laboratory products sector.
- Profitability Fluctuations: Despite the sales growth, net earnings for fiscal year 2026 were $9.62 million, down 15.5% from $11.41 million the previous year, reflecting profitability pressures amid high costs and market volatility, necessitating further cost optimization to maintain margins.
- Strong International Performance: International sales reached $67.11 million, a 9.9% increase, demonstrating the company's resilience in the global market and robust project backlog despite heightened geopolitical uncertainties, bolstering confidence in future growth prospects.
- Improved Balance Sheet: The company successfully reduced long-term debt by approximately $20 million in fiscal year 2026, improving its debt-to-equity ratio from 0.99 to 0.61, indicating significant progress in financial health and laying a solid foundation for future expansion and acquisitions.
See More
Kewaunee Scientific Reports Fiscal Year 2026 Earnings
- Earnings Highlights: Kewaunee Scientific reported a Q4 GAAP EPS of $1.13, with revenue of $71.4 million reflecting a 7.5% year-over-year decline, indicating resilience amid market challenges.
- Annual Sales Growth: The company achieved $281.99 million in sales for fiscal year 2026, representing a 17.3% increase from $240.47 million in the previous year, showcasing positive performance in product demand and market share.
- Profitability Changes: Pre-tax earnings for the fiscal year were $13.73 million, down from $14.79 million the prior year, while net earnings decreased from $11.41 million to $9.62 million, reflecting the impact of cost pressures on profitability.
- Decline in EPS: Diluted earnings per share fell to $3.22 from $3.83 in the previous fiscal year, indicating challenges in profitability that may affect investor confidence.
See More
Kewaunee Scientific to Release Q4 and FY 2026 Financial Results on June 23
- Earnings Release Plan: Kewaunee Scientific Corporation plans to release its fourth quarter and fiscal year 2026 financial results on June 23, 2026, after market close, which is expected to provide investors with crucial performance data and future outlook.
- Company Background: Founded in 1906, Kewaunee is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, including steel and wood casework, fume hoods, and biological safety cabinets, showcasing its strong industry presence.
- Acquisition Details: The recently acquired subsidiary, Nu Aire, specializes in manufacturing biological safety cabinets and ultralow freezers, which complements Kewaunee's product portfolio and enhances its competitive edge in the market.
- Global Operations: Kewaunee operates multiple sales and manufacturing facilities across the U.S., India, and other countries, demonstrating its extensive international footprint and capability to serve global customers.
See More
Kewaunee Scientific Q3 Financial Highlights
- Earnings Performance: Kewaunee Scientific reported a Q3 GAAP EPS of $0.23, indicating stability in profitability despite facing market challenges.
- Revenue Growth: The company achieved revenues of $69.4 million in Q3, reflecting a year-over-year increase of 3.3%, showcasing sustained demand in the laboratory equipment market and an expanding customer base.
- Market Performance Analysis: Although the revenue growth rate is modest, the stable profitability and slight increase suggest that the company maintains a solid competitive position in the industry, potentially attracting more investor interest.
- Future Outlook: Kewaunee Scientific's financial performance lays a foundation for future growth, and management may leverage this positive trend to drive new product development and market expansion strategies.
See More
